Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 7/20 | 0.67 |
| ▸ | PTGDR | Q13258 | 7/20 | 0.67 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.67 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.67 |
| ▸ | PTGFR | P43088 | 1/20 | 0.67 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.67 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.40 |
| ▸ | KCNQ4 | P56696 | 2/20 | 0.40 |
| ▸ | KCNQ5 | Q9NR82 | 2/20 | 0.40 |
| ▸ | FABP4 | P15090 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20541688 | 0.90 | PTGER4 (0.64) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL30498013 | 0.90 | PTGER4 (0.64) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL20542163 | 0.90 | PTGER4 (0.62) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL20542052 | 0.89 | PTGER4 (0.64) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL22276038 | 0.89 | PTGER4 (0.66) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL26254084 | 0.89 | PTGER4 (0.63) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL20541857 | 0.89 | PTGER4 (0.63) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL30498014 | 0.89 | PTGER4 (0.63) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL22392940 | 0.88 | PTGER4 (0.62) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL26254025 | 0.88 | PTGER4 (0.62) | PTGER4PTGDRTBXA2RPTGER1PTGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11738009-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11638704-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20210387985-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TEMPEST THERAPEUTICS, INC. | 2021-12-16 | — | — | US | disclosed |
| US-11066405-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210008046-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TEMPEST THERAPEUTICS, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20200283438-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TEMPEST THERAPEUTICS, INC. | 2020-09-10 | — | — | US | disclosed |
| EP-3612517-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Tempest Therapeutics, Inc. (US) | 2020-02-26 | — | — | EP | disclosed |
| WO-2018195123-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TEMPEST THERAPEUTICS, INC. (US) | 2018-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066405-B2 | Bicyclic compounds and their use in the treatment of cancer | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGDR 5/4885TBXA2R 73/4885 |
| US-20210008046-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGDR 5/4885TBXA2R 73/4885 |
| US-11738009-B2 | Bicyclic compounds and their use in the treatment of cancer | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGDR 5/4885TBXA2R 73/4885 |
| US-20210387985-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGDR 5/4885TBXA2R 60/4885 |
| US-11638704-B2 | Bicyclic compounds and their use in the treatment of cancer | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGDR 5/4885TBXA2R 60/4885 |
| US-20200283438-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGDR 5/4885TBXA2R 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.